Variant CJD found for the first time in a plasma-treated haemophiliac
This article was originally published in Scrip
Executive Summary
The issue of pathogens in blood-derived products, which is one of the drivers behind the biotech industry developing recombinant drugs, has again hit the headlines, with the first case of a plasma product-treated haemophiliac testing positive for variant Creutzfeldt-Jakob disease (vCJD).